market-trends is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention BIO International Convention 2026, the most common co-covered peer. Each carries 2 original sources on average. We currently track 1 Healthcare story that mention Feng Ren, all published on June 23, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Feng Ren
market-trends is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention BIO International Convention 2026, the most common co-covered peer. Each carries 2 original sources on average. We currently track 1 Healthcare story that mention Feng Ren, all published on June 23, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 1 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Feng Ren. Shared-story counts are live from our verified record — not editorial picks.
A breakthrough $2.5B collaboration between AI drug discoverer Insilico Medicine and CNS specialist SK Biopharmaceuticals aims to tackle devastating neuroimmune disorders that have long defied conventional drug development. By combining generative AI with established clinical expertise, the partnership could dramatically shorten timelines and deliver first‑in‑class therapies to patients with conditions like Alzheimer's, multiple sclerosis, and rare neuroinflammatory diseases.
Feng Ren is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.
